Supriya Lifescience Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L51900MH2008PLC180452 Incorporated 26 March 2008 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: SUPRIYA · BSE: 543434 Public Limited Company pharma
Market Cap
₹5,030 Cr
SUPRIYA · NSE
Share Price
₹620.15
-0.78% today
Revenue
₹828 Cr
FY 2025-26 · +18.9% YoY
EBITDA
₹294 Cr
Margin 35.6%
Net Profit
₹209 Cr
FY 2025-26 · +11.3% YoY
P/E (TTM)
27.9x
P/B 4.0x
ROE
19.1%
ROCE 25.1%
Authorised capital
₹35 Cr
Registered with MCA

About Supriya Lifescience Limited

Data last updated:

Supriya Lifescience Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 26 March 2008 and has been in existence for over 18 years.

Its director Satish Waman Wagh is #678 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L51900MH2008PLC180452. Its GSTIN is 27AALCS8686A1ZX (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 543434 and NSE: SUPRIYA.

The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹16.1 Cr. It is led by directors including Saloni Satish Wagh (Managing Director) and Shivani Satish Wagh (Managing Director).

Its last annual general meeting (AGM) was held on 24 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹827.87 Cr, a growth of 18.9% compared to the previous year. For the same year it recorded a net profit of ₹209.14 Cr (net margin 25.3%) and EBITDA of ₹294.46 Cr (EBITDA margin 35.6%). The net worth stands at ₹1,197.74 Cr (up 20.2% YoY). Total assets are valued at ₹1,205.07 Cr (up 20.1% YoY).

The company has about 627 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Supriya Lifescience. As per MCA filings, the company has open charges of ₹188.41 Cr and satisfied charges of ₹283.96 Cr on record. Court records list 28 cases involving the company, including 21 filed by the company and 7 filed against it; 11 cases are pending. The company has 18 deals on record (12 market trades, 4 secondary share transfers, 1 ipo), with disclosed funding of ₹3.4 Cr; the latest was in November 2024. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 224 overdue payments to 39 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website supriyalifescience.com.

Company details

CIN L51900MH2008PLC180452
Registration Number 180452
Incorporation Date 26 March 2008
ROC Mumbai
Listing Status Listed - Listed on NSE (SUPRIYA); Listed on BSE (543434)
Company Status Active
Compliance Status Active Compliant

CIN history

Supriya Lifescience has one previous CIN (Corporate Identification Number): U51900MH2008PLC180452. The current CIN is L51900MH2008PLC180452, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L51900MH2008PLC180452Current
U51900MH2008PLC180452Previous

Recognitions & Rankings of Supriya Lifescience

India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Supriya Lifescience Limited's registered office is in Mumbai, Maharashtra. Its website is supriyalifescience.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    207/208 Udyog Bhavan Sonawala Road Goregaon (East), Mumbai, Maharashtra, India – 400063
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Supriya Lifescience Limited, buy the company report.

Comprehensive company report
Supriya Lifescience Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Supriya Lifescience operates one associated brand: Supriya Lifescience. Each brand links to its own profile.

BrandDescriptionWebsite
Active pharmaceutical ingredients and intermediates are manufactured.supriyalifescience.com

Business activity

The main business activity of Supriya Lifescience is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Supriya Lifescience Limited, buy the company report.

Financials of Supriya Lifescience Limited

FY 2025-26 filings available

Supriya Lifescience Limited reported revenue of ₹827.87 Cr (up 18.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹828 Cr
+18.9% YoY
EBITDA
₹294 Cr
+12.9% YoY
Profit After Tax
₹209 Cr
+11.3% YoY
Net Worth
₹1,198 Cr
+20.2% YoY
Total Assets
₹1,205 Cr
+20.1% YoY
Total Debt
₹5.44 Cr
+1.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue828696570461530391312
Revenue growth+18.9%+22.1%+23.7%-13.0%+35.5%+25.5%-
EBITDA29426117612921417398.38
EBITDA margin+35.6%+37.5%+30.9%+28.0%+40.4%+44.3%+31.6%
Profit before tax27524816612320716796.19
Net profit20918811989.9415212473.35
Net profit margin+25.3%+27.0%+20.9%+19.5%+28.6%+31.6%+23.5%
EPS (₹)25.9823.3514.8011.1618.8616.8950.11
Balance sheet
Total assets1,2051,003822728646362253
Net worth1,198997815699616269149
Total debt5.445.385.4922.4727.4272.1982.21
Cash & bank78.8779.1574.9615822889.2874.71
Net working capital412355321386420190120
Cash flow
Cash from operations18616511363.6148.8075.89117
Cash from investing(176)(152)(174)(124)(59.82)(46.80)(25.14)
Cash from financing(9.88)(8.23)(22.36)(10.28)150(14.52)(29.23)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue206190277206200145184186
Revenue growth (YoY)+3.2%+30.8%+50.2%+11.2%+20.3%-9.7%--
Other income2.292.653.482.612.732.672.982.10
Total expenses16114217913512793.37117120
EBITDA45.4047.4697.6271.6272.6451.7067.5865.95
EBITDA margin+22.0%+25.0%+35.3%+34.7%+36.4%+35.6%+36.7%+35.5%
Depreciation9.468.948.506.826.646.456.084.96
Interest0.460.370.470.490.420.510.420.51
Profit before tax37.7740.8092.1366.9268.3147.4164.0662.58
Tax8.5316.7517.9017.2417.8912.6313.6815.80

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue206190277206200145184186
Revenue growth (YoY)+3.2%+30.8%+50.2%+11.2%+20.3%-9.7%--
Other income2.292.653.482.612.732.672.982.10
Total expenses16114217913512793.37117120
EBITDA45.4047.4697.6271.6272.6451.7067.5865.95
EBITDA margin+22.0%+25.0%+35.3%+34.7%+36.4%+35.6%+36.7%+35.5%
Depreciation9.468.948.506.826.646.456.084.96
Interest0.460.370.470.490.420.510.420.51
Profit before tax37.7740.8092.1366.9268.3147.4164.0662.58
Tax8.5316.7517.9017.2417.8912.6313.6815.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue828696570461530391312
Revenue growth+18.9%+22.1%+23.7%-13.0%+35.5%+25.5%-
Other income11.499.8210.649.497.585.0111.07
Total expenses533436394332316218213
Employee cost96.6880.5267.6455.5849.0832.7618.88
EBITDA29426117612921417398.38
EBITDA margin+35.6%+37.5%+30.9%+28.0%+40.4%+44.3%+31.6%
Depreciation28.4120.4415.8111.8210.126.766.41
Interest2.771.815.153.084.204.086.85
Profit before tax27524816612320716796.19
Tax65.6660.5346.5833.6355.4443.7122.84
Net profit20918811989.9415212473.35
Net profit margin+25.3%+27.0%+20.9%+19.5%+28.6%+31.6%+23.5%
EPS (₹)25.9823.3514.8011.1618.8616.8950.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.1016.1016.1016.1016.1014.6414.64
Reserves & surplus1,182981799683600254134
Shareholders' funds (net worth)1,198997815699616269149
Secured loans0.000.000.0016.6321.3066.3878.12
Unsecured loans5.445.385.495.846.125.814.09
Total debt5.445.385.4922.4727.4272.1982.21
Total liabilities--822728646362253
Assets
Gross block799534371306223123115
Net block68945331026219010098.58
Capital work in progress35.5514814967.6343.4178.7940.21
Investments98.5263.2463.8025.300.050.050.05
Inventories16011885.2511692.3172.4849.46
Sundry debtors21913411284.6611573.5051.63
Cash & bank balances78.8779.1574.9615822889.2874.71
Loans & advances74.3911012610762.1430.2119.81
Total current assets532442398465498265196
Total current liabilities12186.8776.6478.8077.5875.9075.57
Net working capital412355321386420190120
Total assets1,2051,003822728646362253
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash79.1574.9615822889.2874.7112.40
Net cash from operating activities18616511363.6148.8075.89117
Net cash from investing activities(176)(152)(174)(124)(59.82)(46.80)(25.14)
Net cash from financing activities(9.88)(8.23)(22.36)(10.28)150(14.52)(29.23)
Net change in cash(0.29)4.20(82.63)(70.33)13914.5762.31
Closing cash78.8779.1574.9615822889.2874.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+18.9%+22.1%+23.7%-13.0%+35.5%+25.5%-
EBITDA growth+12.9%+48.2%+36.6%-39.8%+23.6%+76.0%-
PBT growth+10.6%+50.0%+34.2%-40.4%+23.9%+73.9%-22.0%
Net income growth+11.3%+57.8%+32.4%-40.8%+22.8%+68.5%-
Revenue CAGR (3Y)+21.6%+9.5%+13.4%+13.9%+24.0%+22.5%+19.3%
EBITDA CAGR (3Y)+31.7%+6.8%+0.6%+9.4%+17.8%+99.1%+78.2%
Profitability & leverage
Net income margin+25.3%+27.0%+20.9%+19.5%+28.6%+31.6%+23.5%
Return on capital employed+25.1%+27.4%+22.1%+18.4%+42.0%+55.8%+46.5%
Return on net worth+19.1%+20.7%+15.7%+13.7%+34.3%+59.2%+60.4%
Debt / equity0.000.010.020.040.110.370.71
Long-term debt / equity0.000.010.010.010.010.010.04
Interest cover1.040.753.212.632.062.457.45
Efficiency & per share
Fixed asset turnover1.371.731.911.953.403.622.98
Inventory turnover6.587.686.444.967.147.077.77
Debtors turnover5.176.366.595.176.246.895.59
EPS (₹)25.9823.3514.8011.1618.8616.8950.11
Dividend per share (₹)1.001.000.800.600.600.5410.00
Book value per share (₹)148.81123.84101.3186.9176.5036.70101.84

To see the full year-wise statements and ratios of Supriya Lifescience Limited, buy the company report.

Board of directors of Supriya Lifescience Limited

Supriya Lifescience has 10 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Smita Satish WaghWhole-Time Director26 Mar 200818 Years 7 MonthsCurrent
Neelam Yashpal AroraDirector25 Mar 20215 Years 7 MonthsCurrent
Balasaheb Gulabrao SawantWhole-Time Director26 May 20233 Years 5 MonthsCurrent
Satish Waman WaghWhole-Time Director26 Mar 200818 Years 7 MonthsCurrent
Saloni Satish WaghManaging Director01 Jul 20224 Years 4 MonthsCurrent
Shivani Satish WaghManaging Director01 Jul 20224 Years 4 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Auditor

Supriya Lifescience Limited is audited by Kakaria and Associates LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Kakaria and Associates LLPFY 2025104558W/ W100601

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 68.30%, foreign institutional investors hold 6.20%, domestic institutional investors hold 5.30% and retail and other public shareholders hold 20.20%.

Promoters: 68.30%DII (Domestic Institutional): 5.30%FII (Foreign Institutional): 6.20%Retail & Others: 20.20%
Sep 2026
QUARTER
68.30% Promoters
5.30% DII (Domestic Institutional)
6.20% FII (Foreign Institutional)
20.20% Retail & Others
Promoter holding - history
Now 68.30% · Sep 2026High 68.30% · Dec 2025Low 68.30% · Dec 2025
67%67.8%68.5%69.3%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 68.30%Mar 2026: 68.30%Jun 2026: 68.30%Sep 2026: 68.30%68.30%68.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters68.30%68.30%68.30%68.30%
Public31.70%31.70%31.70%31.70%

Charges & borrowings

Open charges
₹188.41 Cr
Satisfied charges
₹283.96 Cr
Breakdown by lending institutions
Others₹127.00 Cr
Axis Bank Limited₹44.00 Cr
The Saraswat Cooperative Bank Ltd₹12.91 Cr
The Saraswat Co-Op Bank Ltd₹4.50 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
06 Jun 2026101381192Others₹40 CrOpen
03 May 2024100916191Axis Bank Limited₹44 CrOpen
17 Apr 2024100904329Others₹30 CrOpen
05 Jul 201210368165The Saraswat Cooperative Bank Ltd₹2 CrOpen
27 Jun 200910166123The Saraswat Cooperative Bank Ltd₹10.91 CrOpen

To see the full charge records of Supriya Lifescience Limited, buy the company report.

Total charge records: 46 View all charges

Deals & funding

Supriya Lifescience Limited has 18 deals on record (12 market trades, 4 secondary share transfers, 1 ipo), with disclosed funding of ₹3.4 Cr; the latest was in November 2024.

Total deals
18
Market trades
12
Secondary share transfers
4
IPO
1
Funding round
1
Disclosed funding
₹3.4 Cr

Deals on record (5 of 18)

WhenDealAmountParties
Nov 2024Market trade₹45.93 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Aug 2024Market trade₹32.16 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Feb 2024Market trade₹21.49 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Dec 2023Market trade₹14.27 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
May 2023Market trade₹10.02 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP

To see the full deal history of Supriya Lifescience Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Supriya Lifescience Limited was last rated by Icra on 26 Jul 2021.

Rating agencyRated onRating
Icra26 Jul 2021

To see the full credit ratings and regulatory alerts of Supriya Lifescience Limited, buy the company report.

MSME payment delays

Supriya Lifescience Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 224 overdue payments to 39 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 39)

SupplierAmount dueDue sinceReported on
Spectralab Instruments Private Limited
Resicast
Amjey Chem Trade Private Limited
Acid Industries
an individual supplier

To see the full MSME payment records of Supriya Lifescience Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Supriya Lifescience Limited has a workforce of 627 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
627
Active EPFO establishments
1
Employee growth
19%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27627
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17
FY 2015-16

To see the full employee and EPFO history of Supriya Lifescience Limited, buy the company report.

GST

Supriya Lifescience has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AALCS8686A1ZXMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Supriya Lifescience Limited, buy the company report.

Recent activity

Supriya Lifescience Limited has 29 board changes on record since 2008: 21 appointments and 8 cessations. The latest: Kothandaraman Hari was appointed as Additional Director on 09 Feb 2026.

Charges
A charge registered on 26 Jun 2025 via Charge ID 101126368 with Idbi Trusteeship Services Limited was fully satisfied on 20 Jul 2026.
Charges
A charge with Others amounted to Rs. 40.00 Cr with Charge ID 101381192 was registered on 06 Jun 2026.
Filing
Supriya Lifescience Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Appointed
Kothandaraman Hari was appointed as Additional Director.
Appointed
Manish Ishwarlal Panchal was appointed as Additional Director.
AGM
Supriya Lifescience Limited last Annual general meeting of members was held on 24 Sep 2025 as per latest MCA records.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 114.00 Cr with Charge ID 101126368 was registered on 26 Jun 2025.
Ceased
Bhairav Manojbhai Chokshi ceased to be Director.
Ceased
Kedar Shankar Karmarkar ceased to be Director.
Appointed
Ganapati Dadasaheb Yadav was appointed as Additional Director.
Appointed
Sunil Subhash Bhagwat was appointed as Additional Director.
Ceased
Rajeev Kumar Jain ceased to be CEO.

109 earlier events are in the company report.

News

SUPRIYA: Q2 SL NET PROFIT 292M RUPEES VS 504M (YOY)
06 Nov 2026 · Exchange Update
SUPRIYA: Q2 EBITDA 454M RUPEES VS 726.5M (YOY); Q2 EBITDA MARGIN 22.01% VS 36.35% (YOY)
06 Nov 2026 · Exchange Update
SUPRIYA: Q2 REVENUE 2.06B RUPEES VS 2B (YOY)
06 Nov 2026 · Exchange Update
Supriya Lifescience: Hon'ble High Court Allows Provisional Release Of 200 Kg Ketamine Hydrochloride Consignment; Subject To Deposit Of ₹72 Lakh With Customs; Adjudication And Criminal Proceedings May Continue.
23 Sep 2026 · Exchange Update

Frequently asked questions

Supriya Lifescience is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 26 March 2008 (18+ years old) and is registered under CIN L51900MH2008PLC180452. Listed on BSE: 543434 and NSE: SUPRIYA.

Supriya Lifescience reported revenue of ₹827.87 Cr for FY 2025-26 (up 18.9% YoY) based on standalone financials.

Supriya Lifescience has 10 current directors:

The latest financial statements of Supriya Lifescience on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 24 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Supriya Lifescience is 27AALCS8686A1ZX, registered in Maharashtra.

The CIN (Corporate Identification Number) of Supriya Lifescience is L51900MH2008PLC180452. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Supriya Lifescience is a listed company as per MCA records. Its shares are listed on both BSE (code: 543434) and NSE (symbol: SUPRIYA).

Supriya Lifescience has 28 court cases on record: 21 filed by the company and 7 filed against it. 11 are pending. Most are in the district courts.

Supriya Lifescience was incorporated on 26 March 2008, making it 18+ years old. It is registered with the Registrar of Companies, Mumbai.

Supriya Lifescience has 18 deals on record (12 market trades, 4 secondary share transfers, 1 ipo), with disclosed funding of ₹3.4 Cr; the latest was in November 2024.

Kothandaraman Hari was appointed as Additional Director on 09 Feb 2026. Manish Ishwarlal Panchal was appointed as Additional Director on 09 Feb 2026. Bhairav Manojbhai Chokshi ceased to be Director on 01 Feb 2025. Supriya Lifescience has 29 board changes on record in total.